A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
Latest Information Update: 30 May 2025
At a glance
- Drugs BPRDP 056 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Taivex Therapeutics
Most Recent Events
- 25 May 2025 Planned number of patients changed from 30 to 40.
- 21 Nov 2024 Planned End Date changed from 31 Dec 2025 to 31 Jul 2027.
- 21 Nov 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2026.